Home / Business and Economy / Pfizer's Cash Flow: A Growth Wait or Decline?
Pfizer's Cash Flow: A Growth Wait or Decline?
15 Sep
Summary
- Pfizer generates free cash flow worth 7.0% of its market value annually.
- Company management forecasts growth to resume from 2029 onwards.
- Revenue has contracted by 5.2% annually over three years.
Pfizer (PFE) is currently generating substantial free cash flow, equivalent to 7.0% of its market value annually. This strong performance is attributed to high operating margins, significantly exceeding the S&P 500 median. Management projects a return to growth commencing in 2029, with the company offering a 6.2% dividend yield to compensate investors for the interim waiting period.
Despite its robust cash generation, Pfizer faces revenue contraction, down 5.2% annually over the past three years. The company has reduced its 2026 COVID revenue forecast and noted potential limitations on Paxlovid sales due to weak incidence. Excluding COVID products, operational growth was 5% in the June quarter, and full-year 2026 revenue guidance was raised.
Reported profits are impacted by pipeline challenges, including a $4.3 billion noncash impairment in the June quarter following a failed lung cancer trial. To counter these issues, Pfizer is implementing cost programs targeting roughly $9.7 billion in net savings through 2029. The company is also advancing its pipeline, with expanded FDA approval for Padcev and the development of berobenatide for obesity, aiming for a first approval in 2028.
